Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether consuming tart cherry juice daily for 12 months reduces the risk of gout attacks during this period. Individuals with an existing gout diagnosis and who have experienced at least one gout flare in the past year will be recruited to participate in this study.


Clinical Trial Description

Gout is a painful and often debilitating condition affecting around 3% of adults in the UK. It is a type of inflammatory arthritis caused by high levels of uric acid which is deposited as crystals in joints, resulting in painful gout flares. Cherries and cherry products have received attention for their possible role in gout management owing to their anti-inflammatory and anti-oxidant properties. Their consumption has been associated with a lower risk of gout attacks in one observational study. The consumption of cherries is also endorsed by several gout information websites and in the British Society of Rheumatology's 2017 guidelines for the management of gout. However, there is limited evidence underpinning these claims and existing studies tend to be short in duration and have small participant numbers. Gout attacks are sporadic in nature and so a long-term trial is required to clarify the therapeutic effect of cherries on gout attack risk. The investigators are aiming to recruit 120 participants who have had at least one gout flare in the previous 12 months. Using the work of Rothenbacher et al., 2011, the chance of these individuals experiencing at least one attack in the next 12 months has been calculated at 11%. It is predicted that treatment with daily cherry juice consumption will reduce gout flare recurrence (primary outcome measure) to 1/4 of the rate of the actual recurrence i.e. to 2.7%. Using these figures, a sample size of 93 participants would provide power of 0.95 at a significance level of 0.05. A sample size of 120 participants allows for an approximate 20% attrition rate. Participants will consume either 30 mL tart cherry juice (CherryActive) diluted to 250 mL with water or a fruit-flavoured placebo drink daily with breakfast for 12 months. Participants will be followed up at 6 and 12 months at the investigators' laboratory to study changes in gout flare frequency and intensity, uric acid levels and levels of inflammation. This will help determine if tart cherry juice could help reduce or even prevent gout attacks. Additionally, as gout is associated with increased cardiovascular disease (CVD) risk, changes in CVD risk markers, including blood pressure, arterial stiffness and cholesterol levels, will also be assessed. Participants will be recruited through the use of posters, advertising on the UK Gout Society website, emails to large organisations and through letters sent from General Practitioners' (GP) surgeries to eligible patients. Potentially eligible patients will be identified by surgery staff using their patient database before contact information is passed to the research team at the surgery to prepare and send out invitation letters. As this method of recruitment involves accessing patient identifiable data (name and home address) prior to patient consent being given, an application to the Confidentiality Advisory Group (CAG) will be submitted for consideration. A general linear mixed model analysis will be used to assess the effect of treatment allocation, time and their interaction on both primary and secondary outcome measures. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03621215
Study type Interventional
Source Sheffield Hallam University
Contact
Status Active, not recruiting
Phase N/A
Start date July 15, 2019
Completion date April 2021

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05522504 - Distribution of Immune Cells and Their Subtypes in Peripheral Blood of Gout
Recruiting NCT03933007 - Relation Between Blood Concentration of Colchicine and Response to Colchicine Treatment in Gout Flare Phase 4
Not yet recruiting NCT04069325 - Efficacy and Safety of Simiaowan in Prevention of Acute Flares in Chronic Gout Patients Initiating Febuxostat Therapy N/A
Recruiting NCT05586958 - Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients Phase 3
Active, not recruiting NCT06197828 - Novel Biomarkers for Early Renal Injury in Children With Sepsis
Recruiting NCT05586971 - Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients Phase 3
Not yet recruiting NCT04849312 - Prediction of 30-Day Readmission Using Machine Learning
Active, not recruiting NCT04784351 - Prediction of Expected Length of Hospital Stay Using Machine Learning
Active, not recruiting NCT05045742 - Prediction of Patient Deterioration Using Machine Learning
Completed NCT03203759 - Hospital-Level Care at Home for Acutely Ill Adults N/A
Recruiting NCT05936268 - Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare Phase 2
Recruiting NCT05658575 - Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare Phase 2/Phase 3
Recruiting NCT03524222 - Home Hospital for Suddenly Ill Adults N/A
Not yet recruiting NCT06273813 - Treatment of Topical Ketorolac Gel in Acute Gouty Flare Phase 1
Completed NCT04531280 - Rural Home Hospital: Proof of Concept N/A
Completed NCT05256303 - Rural Hospital-Level Care at Home for Acutely Ill Adults N/A
Not yet recruiting NCT06207045 - The Effects of Limb Elevation During Gout Flare Episodes N/A
Completed NCT04080570 - Remote Physician Care for Home Hospital Patients N/A